Agent consensus
OVERWEIGHT
Multi-agent note output
AMGN
Equity research — AMGN (as of 2026-08-07)
Updated Aug 7, 2026
Coverage
AMGN
Freshness
3 days ago
Market chart
Price context alongside the research narrative.
How the call aged
A simple read on whether this desk view matched what happened in the market over the next 5 trading days, with recent price context from the as-of date.
Desk view: OVERWEIGHTNot gradedVs peers: Stronger than mostAwaiting market data
Price move
—
2026-08-07 → awaiting data
5-day trend
+6.70%
20-day trend
+13.09%
Recent volatility
+30.30%
vs SPY (5d): +3.18%
Close 410.95 → —
Desk briefing
Coverage of the Q2 2026 earnings call highlights revenue above $10 billion and ~10% year-over-year growth, driven by Repatha and UPLIZNA, with full-year 2026 guidance raised. A separate piece (Aug 6–7) notes that growth across cardiovasc...
Full research note
Presentation-ready note with specialist analyst agents, bull and bear agent debate, trader agent synthesis, risk challenge, and portfolio sign-off.
WebserviceX.NET Research Desk
AMGN Equity Research Note
Summary
Coverage of the Q2 2026 earnings call highlights revenue above $10 billion and ~10% year-over-year growth, driven by Repatha and UPLIZNA, with full-year 2026 guidance raised. A separate piece (Aug 6–7) notes that growth across cardiovasc...
Bias
OVERWEIGHT
Horizon
Short to medium term
Key risk
Event-driven repricing risk if expectations diverge from incoming evidence.
Catalyst watch
This is execution guidance for the trading overlay, not a separate rating — the structural view remains the 12-month investment rating.